Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September

Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September

Source: 
Motley Fool
snippet: 

Thanks to a handful of initial public offerings (IPOs) in the last year, individual investors can now own liquid biopsy stocks. Thanks to awful performance last month, most of them are trading at their lowest levels in months -- or ever.